Basilea Snaps Up Another Antibiotics Program As Pipeline Swells

The company has bagged a preclinical program from struggling Swiss biotech Spexis for $2.3m upfront, its fourth deal in as many months.

Swiss flag
2024 looking promising for Switzerland's Basilea • Source: Shutterstock

After a busy 2023 on the business development front, Basilea Pharmaceutica Ltd. has started the year by adding more assets to its pipeline with the acquisition of a preclinical antibiotics program from fellow Swiss biotech Spexis AG.

Key Takeaways
  • Basilea has been restocking its pipeline through a number of deals

The acquired antibiotics are of a novel class, targeting lipopolysaccharide transport in Gram-negative bacteria, which have been highlighted by the...

More from Deals

More from Business